Literature DB >> 11852993

Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.

Maura Pieretti1, Claudia Hopenhayn-Rich, Nada H Khattar, Yangming Cao, Bin Huang, Thomas C Tucker.   

Abstract

Epidemiological studies have established associations between various reproductive factors and risk of ovarian cancer; it has also been observed that some of these risk factors are only associated with specific histological subgroups. To investigate the correlation of genetic alterations with these risk factors, we examined a consecutive series of 158 ovarian cancer cases treated at the University of Kentucky (1990-96). Common molecular genetic alterations (LOH on chromosome 17, P53 alterations, K-RAS mutations), histological and clinical characteristics of the disease, demographic patient information and survival were evaluated. These latter data were from the Kentucky Cancer Registry. Univariate analysis showed higher frequencies of chromosome 17 loss and P53 mutations in tumors of advanced stage and grade, and in older and post-menopausal women. Non-mucinous tumors were more likely to be classified as late stage, high-grade cancers, and to have chromosome 17 loss and P53 mutations. Survival analysis indicated that stage was the only independent significant variable. When stage was the outcome variable in multiple logistic regression analysis, histology and chromosome 17 loss were significantly associated with poor survival. This case-case study provides evidence that ovarian cancers of mucinous and non-mucinous histology are significantly different with respect to clinical characteristics, survival and molecular alterations. It also lends support to the hypothesis that ovarian cancer is a heterogeneous disease with distinct etiological factors and clinical outcomes, which may require different approaches to treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11852993     DOI: 10.1081/cnv-120000361

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  10 in total

1.  Protective effect of Echinacea purpurea (Immulant) against cisplatin-induced immunotoxicity in rats.

Authors:  Abdelazeem Ali Khalaf; Shaymaa Hussein; Adel Fathy Tohamy; Sherif Marouf; Hanan Dawood Yassa; Amr Reda Zaki; Anupam Bishayee
Journal:  Daru       Date:  2019-05-27       Impact factor: 3.117

Review 2.  Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.

Authors:  Ignacio Romero; Robert C Bast
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

3.  Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer.

Authors:  HanByoul Cho; Jae-Hoon Kim
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

4.  Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.

Authors:  Janneta Tcherkassova; Carolina Abramovich; Rafael Moro; Chen Chen; Ralph Schmit; Angela Gerber; Ricardo Moro
Journal:  Tumour Biol       Date:  2011-05-28

Review 5.  Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

Authors:  Nikos G Gavalas; Alexandra Karadimou; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  Clin Dev Immunol       Date:  2011-01-24

6.  Genome-wide significant risk associations for mucinous ovarian carcinoma.

Authors:  Linda E Kelemen; Kate Lawrenson; Jonathan Tyrer; Qiyuan Li; Janet M Lee; Ji-Heui Seo; Catherine M Phelan; Jonathan Beesley; Xiaoqing Chen; Tassja J Spindler; Katja K H Aben; Hoda Anton-Culver; Natalia Antonenkova
Journal:  Nat Genet       Date:  2015-06-15       Impact factor: 38.330

Review 7.  Recent Insights into Mucinous Ovarian Carcinoma.

Authors:  Francesca Ricci; Roberta Affatato; Laura Carrassa; Giovanna Damia
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923

8.  Mucinous Ovarian Tumors With Anaplastic Mural Nodules: Case Report.

Authors:  Xinxin Zou; Hao Huang; Qingyu Zhang; Zhen Ma; Yumei Chen; Weifeng Wu; Aizhen Fu
Journal:  Front Med (Lausanne)       Date:  2021-12-14

Review 9.  Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.

Authors:  Tadahiro Shoji; Shunsuke Tatsuki; Marina Abe; Hidetoshi Tomabechi; Eriko Takatori; Yoshitaka Kaido; Takayuki Nagasawa; Masahiro Kagabu; Tsukasa Baba; Hiroaki Itamochi
Journal:  Cancers (Basel)       Date:  2021-12-04       Impact factor: 6.639

10.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.